COUP-TFII suppresses colorectal carcinoma resistance to doxorubicin involving inhibition of epithelial-mesenchymal transition.

COUP-TFII suppresses colorectal carcinoma resistance to doxorubicin involving inhibition of epithelial-mesenchymal transition.